Artios Pharma

Babraham-based Artios Pharma is a clinical stage biotech pioneering the development of novel small molecule therapeutics that target the DNA damage response process to treat patients with a broad range of cancers.

Courtesy – Artios Pharma

Artios has raised $320m to date from investors and strategic partners, including a $153m Series C financing in July 2021.

The company has strategic partnerships with Merck KGaA and Novartis and research collaborations with Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute.

Career opportunities at Artios Pharma

Newsdesk

news@businessweekly.co.uk